References

1. Goetz CG: Neurotoxins in Clinical Practice. New York, Spectrum Publications, 198 5.

2. Hartman D: Neuropsychological Toxicology: Identification and Assessment of Human Neurotoxic Syndromes. New York, Pergamon Press, 19 88.

3. Bolla KI: Neuropsychological evaluation for detecting alterations in the central nervous system after chemical exposure. Regul Toxicol Pharmacol 1996;24:548-55■.

4. Bolla-Wilson K, Bleecker ML: Neuropsychological impairment following inorganic arsenic exposure. j Occup Med 1987;29:500-503

5. Wittmers Jr LE, Wallgren J, Alich A, et al: Lead in bone. IV. Distribution of lead in the human skeleton. Arch Environ Health 1988;43:381-39-,

6. Somervaille LJ, Chettle DR, Scott MC, et al: In vivo tibia lead measurements as an index of cumulative exposure in occupationally exposed subjects. Br j Ind Med 1988;45:174-181

7. Davis JM, Elias RW, Grant LD: Current issues in human lead exposure and future development in the regulation of lead. Neurotoxicology 1993;14:15-28

8. Annest JL, Pirkle JL, Makuc D, et al: Chronological trend in blood levels between 1976 and 1980. n Engl j Med 1983;308:1373-1377

9. Bellinger D, Levinton A, Waternaux C, et al: Longitudinal analyses of prenatal and postnatal lead exposure and early cognitive development. n Engl j Med 1987;316:1037-1043

10. Needleman HL, Schell A, Bellinger D, et al: The long-term effects of exposure to low doses of lead in childhood: An 11 year follow-up report. n Engl j Med 1990;322:83-88

11. Todd AC, McNeill FE, Palethorpe JE, et al: In vivo x-ray fluorescence of lead in bone using K x-ray excitation with 109 Cd sources: Radiation and dosimetry studies. Environ Res 1992;57:117-132

12. Hanninen H, Hernberg S, Mantere P, et al: Psychological performance of subjects with low exposure to lead. j Occup Med 1978;20:683

13. Baker EL, Feldman RG, White RF, et al: The role of occupational lead exposure in the genesis of psychiatric and behavioral disturbances. Acta Psychiat Scand 1983;303:38-48

14. Ryan CM, Morrow L, Parkinson D, et al: Low level lead exposure and

neuropsychological functioning in blue collar males. Int j Neurosci 1987;36:29-39

15. Balbus-Kornfeld J, Stewart W, Bolla KI, et al: The effect of cumulative lead exposure on neurobehavioral test performance in adults. j Occup Environ Med 1995;52:2-12

16. Schwartz BS, Bolla KI, Stewart W, et al: Decrements in neurobehavioral performance associated with mixed exposure to organic and inorganic lead. Am j Epidemiol 1993;137:1006-102-.

17. Mena I, Court J, Fuenzalida S, et al: Modification of chronic manganese poisoning treatment with L-dopa or 5-OH tryptophane. n Engl j Med 1970;282:5-10

18. Cotzias GC, Horiuchi K, Fuenzalida S, et al: Chronic manganese poisoning: Clearance of tissue manganese concentrations with persistence of the neurological picture. Neurology 1968;18:376-382

19. Shiraki H: Neuropathological aspects of organic mercury intoxication. In Vinken PJ, Bruyn GW (eds): Handbook of Clinical Neurology. Amsterdam, North-Holland, 1979, pp 83-1 6.

20. Chang LW, Dyer RS (eds): Handbook of Neurotoxicology. New York, Marcel Dekker, 199..

21. Hormes J, Filley C, Rosenberg N: Neurologic sequelae of chronic solvent vapor abuse. Neurology 1986;36:698-702

22. Bolla KI, Schwartz BS, Stewart W, et al: A comparison of neurobehavioral function in workers exposed to a mixture of organic and inorganic lead and in workers exposed to solvents. Am j Ind Med

1995;27:231-246

23. Cranmer JM, Goldberg L: Human aspects of solvent neurobehavioral effects. Report of the workshop session on clinical and epidemiological topics. Proceedings of the Workshop on Neurobehavioral Effects of Solvents. Neurotoxicology 1986;7:45-56

24. Mittal BV, Desai AP, Khade KR: Methyl alcohol poisoning: An autopsy study of 28 cases. j Postgrad Med 1991;37:9-13

25. Spencer PS, Couri D, Schaumburg HH: N-Hexane and methyl n-butyl ketone. In Spencer PS, Schaumberg HH (eds): Experimental and Clinical Neurotoxicology. Baltimore, Williams & Wilkins, 1980, pp 456- 75.

26. Benignus VA: Neurobehavioral effects of toluene: A review. Neurobehav Toxicol Teratol 1981;3:408-41!..

27. Feldman RG: Trichlorethylene. In Vinken PJ, Bruyn GW (eds): Handbook of Clinical Neurology. Amsterdam, North-Holland, 1979, pp 457-4(4.

28. Min SK: A brain syndrome associated with delayed neuropsychiatric sequelae following acute carbon monoxide intoxication. Acta PsychiatrScand 1986;73:80-86

29. Gordon MF, Mercandetti M: Carbon monoxide poisoning producing purely cognitive and behavioral sequelae. Neuropsychiat Neuropsychol Behav Neurol 1989;2:145-152.

30. McConnell R: Pesticides and Related Compounds. In Rosenstock L, Cullen MR (eds): Textbook of Clinical Occupational and Environmental Medicine. Philadelphia, W.B. Saunders, 1994, pp 847- 65.

31. Senanayake N, et al: Acute polyneuropathy after poisoning by a new organophosphate insectide. n Engl j Med 1982;306:155-157

32. Baker SR, Williamson CF: The Effects of Pesticides on Human Health. Advances in Modern Environmental Toxicology. Princeton, NJ, Princeton Scientific Co, 199 0.

33. Mayersdorf A, Israeli R: Toxic effects of chlorinated hydrocarbon insecticides on the human electroencephalogram. Arch Environ Health 1974;28:159-163

34. Russell FE: Snake venom poisoning. Vet Human Toxicol 1991;33:584-586

35. Rodichok LD, Barron KD: Neurologic complications of bee sting, tick bite, spider bite, and scorpion sting. In Vinken PJ, Bruyn GW (eds): Handbook of Clinical Neurology. Amsterdam, North Holland, 1979, pp 107-1 4.

36. Hovell WH: Tick paralysis: A review. Mayo Clin Proc 1943; 18:39-49 (Abstract)

37. Gueron M, Ilia R, Sofer S: The cardiovascular system after scorpion envenomation. j Toxicol Clin Toxicol 1992;30:245-258.

38. Misra UK, Sharma VP: Peripheral and central conduction studies in neurolathyrism. j Neurol Neurosurg Psychiatry 1994;57:572-577

39. Weaver AL: Lathyrism: A review. Arthritis Rheum 1967;10:470-474

40. Waksman BH: Experimental study of diphtheric polyneuritis. j Neuropathol Exp Neurol 1961;20:35-45

41. Weinstein L: Tetanus. N Engl J Med 1973;289:1293

42. Arnon SS, Midura TF, Damus K, et al: Honey and other environmental risk factors for infant botulism. jPediatr 1979;94:331-336

43. Barrett DH: Endemic food-borne botulism: Clinical experience 1973-1986 at Alaska Native Medical Center. Alaska Med 1991;33:101-108

44. Levine SR, Brust JCM, Futrell N, et al: Cerebrovascular complications of the "crack" form of alkaloidal cocaine. n Engl J Med 1990;323:699

45. Kaku DA, Lowestein DH: Emergence of recreational drug abuse as a major risk factor for stroke in young adults. Ann Intern Med 1990;113:821

46. Sloan MA, Kittner SJ, Rigamonti D, et al: Occurrence of stroke associated with use/abuse of drugs. Neurology 1991;41:135&

47. Krendel DA, Ditter SM, Frankel MR, et al: Biopsy-proven cerebral vasculitis associated with cocaine abuse. Neurology 1991;40:1092

48. Fredericks RK, Lefkowitz DS, Challa VER, et al: Cerebral vasculitis associated with cocaine abuse. Stroke 1991;22:1437

49. Volkow ND, Fowler JS, Wolf AP, et al: Metabolic studies of drugs of abuse. In Harris L (ed): Problems of Drug Dependence 1990. NIDA Research Monograph 105. Washington, DC, Department of Health and Human Services, 1991, p 47.

50. London ED, Cascella NG, Wong DF, et al: Cocaine-induced reduction of glucose utilization in human brain. Arch Gen Psychiatry 1990;47:567-574

51. Rumbaugh CL, Bergeron T, Gang HCH, et al: Cerebral angiographic changes in the drug abuse patient. Radiology 1971,101:335

52. Rothrock JF, Rubenstein R, Lyden PD: Ischemic stroke associated with methamphetamine inhalations. Neurology 1988;38:589-592

53. Rumbaugh CL, Bergeron T, Scanlon RL, et al: Cerebral vascular changes secondary to amphetamine abuse in the experimental animal. Radiology 1971;101:345

54. Rumbaugh CL, Fang HCH, Higgins RE, et al: Cerebral microvascular injury in experimental drug abuse. Invest Radiol 1976;11:382-394

55. Stafford CR, Bodganoff BM, Green L, et al: Mononeuropathy multiplex as complication of amphetamine angiitis. Neurology 1975;25:570-572

56. Martin WR, Sloan JW, Sapira JD, et al: Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 1971;12:245

57. Pollack MA, Cohen NL, Friedhoff AG: Gilles de la Tourette's syndrome: Familial occurrence and precipitation by methylphenidate therapy. Arch Neurol 1977;34:630-632

58. Bonthala CM, West A: Pemoline induced chorea and Gilles de la Tourette's syndrome. Br J Psychiatry 1983;143:300-302

59. McCann UD, Ridenour A, Shaham Y, Ricaurte G: Serotonin neurotoxicity after (±) 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy): A controlled study in humans. Neuropsychopharmacology 10:129-138

60. Shiffer D, Brignolio F, Giordena MT, et al: Spongiform encephalopathy in addicts inhaling preheated heroin. Clin Neuropathol 1985;4:174

61. Martin WR, Frazer HF: A comparative study of physiological and subjective effects of heroin and morphine administered intravenously in post addicts. J Pharmacol Exp Ther 1961;133:388

62. Lahmeyer HW, Steingold RG: Pentazocine and tripelennamine: A drug abuse epidemic? Int J Addict 1980;15:1219-1232

63. Goodhart LC, Loizou LA, Anderson M: Heroin myelopathy. J Neurol Neurosurg Psychiatry 1982;45:562-563

64. Loizou LA, Boddie HG: Polyradiculoneuropathy associated with heroin abuse. J Neurol Neurosurg Psychiatry 1978;41:855-587

65. Brust JCM, Richter RW: Tetanus in the inner city. ny State J Med 1974;74:1735

66. Davis GC, Williams AC, Markey SP, et al: Chronic Parkinsonism secondary to intravenous injection of neperidine analogs. Psychiatry Res 1979;1:249

67. Langston JW, Ballard P, Teturd JW, et al: Chronic Parkinsonism due to a product of neperidine analog synthesis. Science 1983;219:979-980

68. McCrodden JM, Tipton KF, Sullivan JP: The neurotoxicity of MPTP and the relevance to Parkinson's disease. Pharmacol Toxicol 1990;67:8-13

69. Cadet JL, Ali SF, Rothman RB, et al: Neurotoxicity, drugs of abuse, and the CuZn- superoxide dismutase transgenic mice. MolNeurobiol 1995;11:155-163

70. ACGIH: Threshold Limit Values and Biological Exposure Indices for 1994-1995. Cincinnati, American Conference of Governmental Industrial Hygienists, 199 4.

PreviousNext

Diabetes 2

Diabetes 2

Diabetes is a disease that affects the way your body uses food. Normally, your body converts sugars, starches and other foods into a form of sugar called glucose. Your body uses glucose for fuel. The cells receive the glucose through the bloodstream. They then use insulin a hormone made by the pancreas to absorb the glucose, convert it into energy, and either use it or store it for later use. Learn more...

Get My Free Ebook


Post a comment